Core Viewpoint - A class action securities lawsuit has been filed against Petco Health and Wellness Company, Inc. for alleged securities fraud affecting investors between January 14, 2021, and June 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related business advantages were not sustainable and that its business model, which focuses on premium pet food, was overstated [2]. - It is alleged that the defendants minimized the true extent of the issues facing Petco, including the necessary changes to address these issues and the potential negative impacts on comparable sales [2]. - The lawsuit asserts that the defendants misrepresented Petco's ability to achieve sustainable and profitable growth, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who experienced losses in Petco during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be eligible for compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in 3D Systems Corporation ("3D Systems Corporation" or the "Company") (NYSE: DDD) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of 3D Systems Corporation investors who were adversely affected by alleged securities fraud between August 13, 2024 and May 12, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/3d-s ...

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - Allegations include that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

NEW YORK, July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission-f ...

Core Viewpoint - A class action securities lawsuit has been filed against Reddit, Inc. alleging securities fraud that negatively impacted investors between October 29, 2024, and May 20, 2025 [1] Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the impact of changes in Google Search's algorithm, which led to a significant reduction in traffic to Reddit [2] - It is alleged that the defendants were aware that users were finding answers directly on Google Search, rather than visiting Reddit, which contributed to the decline in user engagement [2] - The lawsuit asserts that the defendants lacked a reasonable basis for their forecasts on user rates and advertising revenues, resulting in materially false and misleading public statements [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 18, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees dedicated to serving clients in complex securities litigation and has been ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance claimed to be closely monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - On July 17, 2024, Elevance announced an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains the active ingredient semaglutide [3]. - Allegations include that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and claimed compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen Inc. made materially false and misleading statements regarding PGN-EDO51, claiming it was more effective and safe than it actually was [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the product's clinical, regulatory, and commercial prospects [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - Hims & Hers Health Inc. is facing potential securities fraud claims following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and selling unapproved products [2][3]. Group 1: Company Actions and Allegations - Hims & Hers is under investigation for making materially false or misleading statements regarding its GLP-1 offerings and the partnership with Novo Nordisk [3]. - The company allegedly engaged in deceptive marketing practices and sold unapproved compounded versions of semaglutide, leading to significant investor concerns [2][3]. Group 2: Market Reaction - Following the announcement of the termination of the partnership with Novo Nordisk, shares of Hims & Hers experienced a decline of over 34% in intraday trading, indicating heightened investor anxiety regarding regulatory compliance and reputational risks [2]. Group 3: Legal Proceedings - Investors who purchased Hims & Hers securities between April 29, 2025, and June 22, 2025, are eligible to seek appointment as lead plaintiff representatives by the deadline of August 25, 2025 [1].